Jasper Therapeutics, Inc.

Distress signal

Moderate confidence (50%)

Updated Oct 17, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Jasper Therapeutics, Inc. was delisted from its exchange (Sep 24, 2026)

Every material event, newest first. History is never overwritten.

Jasper Therapeutics, Inc. was delisted from its exchange
Sep 24, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001788028 Jasper Therapeutics, Inc. 001-39138 2200 Bridge Pkwy Suite #102 Redwood City CA CALIFORNIA 94065 (650) 549-1400 Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00 17 CFR 240.12d2-2(a)(2) Tara Petta AVP 2026-09-24”
Jasper Therapeutics, Inc. received a delisting notice from its exchange
Jun 3, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 3, 2026, Jasper Therapeutics, Inc. (the Company ) received written notice (the Notice ) from The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, for the last thirty consecutive business days, the bid price for the Company s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) ( Rule 5550(a)(2) ). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company…”

Every material source used to build this profile.

SEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001788028 Jasper Therapeutics, Inc. 001-39138 2200 Bridge Pkwy Suite #102 Redwood City CA CALIFORNIA 94065 (650) 549-1400 Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00 17 CFR 240.12d2-2(a)(2) Tara Petta AVP 2026-09-24
View source record
SEC Company Submissions (TIER 1 · UNVERIFIED)
Jasper Therapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — REDWOOD CITY, CA
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 3, 2026, Jasper Therapeutics, Inc. (the Company ) received written notice (the Notice ) from The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, for the last thirty consecutive business days, the bid price for the Company s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) ( Rule 5550(a)(2) ). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company…
View source record

Every derived status, with the rule that produced it.

DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:35 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:12 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.